Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events during study treatment · non‐hospitalised adults with mild COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (revisional procedure) · children and adolescents with obesity
1 finding from 1 review
Serious adverse events (falls) Median · older people at risk of poor health outcomes
It is very uncertain whether comprehensive Geriatric Assessment changes serious adverse events (falls) Median compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: superficial infection · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
It is very uncertain whether the intervention changes adverse events: superficial infection (very low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events (4 weeks' to 180 days' · primary Raynaud's phenomenon
1 finding from 1 review
Adverse events ‐ Gestational diabetes · women with infertility and obesity
It is very uncertain whether preconception lifestyle advice on weight changes adverse events ‐ Gestational diabetes compared with routine care or attention control (very low certainty).
1 finding from 1 review
Adverse events (during intervention)Â · children/adolescents with post‐traumatic stress and related depressive/anxiety symptoms
1 finding from 1 review
Adverse events considered non‐serious · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events/serious adverse events · people with NMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found